Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorChina National Center for Cardiovascular Diseases
About this trial
In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.
Eligibility criteria
Qualifiers
Aged 18 years and above.
Hypertensive patients currently taking at least one antihypertensive medication as recommended by guidelines, and blood pressure is within the target range (<140/90 mmHg).
Left atrial volume index > 34 mL/m² measured by echocardiography;
Average E/e' > 9 measured by echocardiography;
Disqualifiers
History of diabetes.
History of heart failure.
History of myocardial infarction, acute coronary syndrome within the past 6 months, or planned coronary revascularization within the next 6 months
Left ventricular systolic dysfunction, defined as LVEF < 50%.
Trial design
Treatments tested in this trial
- Empagliflozin 10 MG
- Placebo
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov